KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non Operating Income: 2011-2025

Historic Other Non Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 12 years, with Sep 2025 value amounting to $102,000.

  • Jazz Pharmaceuticals' Other Non Operating Income rose 114.55% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 195.19%. This contributed to the annual value of -$8.2 million for FY2024, which is 193.11% down from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Other Non Operating Income stood at $102,000, which was up 147.89% from -$213,000 recorded in Q2 2025.
  • Jazz Pharmaceuticals' Other Non Operating Income's 5-year high stood at $9.4 million during Q4 2023, with a 5-year trough of -$10.5 million in Q1 2022.
  • Moreover, its 3-year median value for Other Non Operating Income was -$457,000 (2024), whereas its average is $49,400.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Other Non Operating Income soared by 735.78% in 2021, and later tumbled by 1,217.71% in 2022.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Other Non Operating Income stood at -$5.6 million in 2021, then spiked by 55.77% to -$2.5 million in 2022, then spiked by 476.83% to $9.4 million in 2023, then crashed by 167.30% to -$6.3 million in 2024, then spiked by 114.55% to $102,000 in 2025.
  • Its last three reported values are $102,000 in Q3 2025, -$213,000 for Q2 2025, and -$6.3 million during Q4 2024.